Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5988387 | 1.00 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL5506332 | 1.00 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL283263 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL283607 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL283262 | 0.98 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL5508178 | 0.96 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL28374186 | 0.96 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| SCHEMBL8259939 | 0.96 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| SCHEMBL21848668 | 0.96 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| SCHEMBL632775 | 0.96 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| CN-110963994-B | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-02-08 | — | — | CN | disclosed |
| EP-3896062-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3862348-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-110963994-A | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-04-07 | — | — | CN | disclosed |
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-8877780-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2057143-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2291365-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| EP-1848433-A2 | METHODS AND COMPOSITIONS USING 4-AMINO-2-(3-METHYL-2,6-DIOXOPIPERIDIN-3-YL)-ISOINDOLE-1-3-DIONE | CELGENE CORPORATION (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060205787-A1 | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione | MULLER GEORGE W | 2006-09-14 | — | — | US | disclosed |
| WO-2006081251-A2 | METHODS AND COMPOSITIONS USING 4-AMINO-2-(3-METHYL-2,6-DIOXOPIPERIDIN-3-YL)-ISOINDOLE-1-3-DIONE | CELGENE CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885CYP19A1 603/4885CYP3A4 3/4885 |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | CRBN, CUL4B, UBQLN1 | CRBN 1/4885CYP19A1 1469/4885CYP3A4 711/4885 |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885CYP19A1 603/4885CYP3A4 3/4885 |
| US-20060205787-A1 | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione | HTR5A, IDO1, HTR3C | CRBN 1786/4885CYP19A1 490/4885CYP3A4 53/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885CYP19A1 603/4885CYP3A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.